AQST vs. DDS
AQST (Aquestive Therapeutics, Inc.) and DDS (Dillard's, Inc.) are both stocks. AQST operates in Drug Manufacturers - Specialty & Generic (Healthcare), while DDS operates in Department Stores (Consumer Cyclical). Over the past 5 years, AQST returned -0.29%/yr vs 35.97%/yr for DDS. At a 0.17 correlation, their price movements are largely independent.
Performance
AQST vs. DDS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, AQST achieves a -35.45% return, which is significantly lower than DDS's 0.66% return.
AQST
- 1D
- -0.95%
- 1M
- 0.97%
- YTD
- -35.45%
- 6M
- -32.85%
- 1Y
- 25.98%
- 3Y*
- 22.65%
- 5Y*
- -0.29%
- 10Y*
- —
DDS
- 1D
- -0.70%
- 1M
- 14.47%
- YTD
- 0.66%
- 6M
- -10.45%
- 1Y
- 58.44%
- 3Y*
- 27.17%
- 5Y*
- 35.97%
- 10Y*
- 30.59%
AQST vs. DDS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
AQST Aquestive Therapeutics, Inc. | -35.45% | 81.46% | 76.24% | 123.92% | -76.81% | -27.29% | -8.08% | -7.62% | -58.14% |
DDS Dillard's, Inc. | 0.66% | 46.81% | 13.47% | 32.05% | 38.66% | 306.41% | -12.71% | 22.76% | -26.19% |
Correlation
The correlation between AQST and DDS is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.19 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.16 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.17 |
Correlation (All Time) Calculated using the full available price history since Jul 25, 2018 | 0.17 |
Fundamentals
AQST:
$511.28M
DDS:
$9.52B
AQST:
-$0.61
DDS:
$42.07
AQST:
9.42
DDS:
1.45
AQST:
$50.27M
DDS:
$6.58B
AQST:
$20.92M
DDS:
$1.82B
AQST:
-$53.08M
DDS:
$985.80M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
AQST vs. DDS — Risk / Return Rank
AQST
DDS
AQST vs. DDS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Aquestive Therapeutics, Inc. (AQST) and Dillard's, Inc. (DDS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| AQST | DDS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.18 | ||
| Sortino ratioReturn per unit of downside risk | -0.96 | ||
| Omega ratioGain probability vs. loss probability | 1.16 | 1.27 | -0.10 |
| Calmar ratioReturn relative to maximum drawdown | 0.43 | 2.42 | -1.99 |
| Martin ratioReturn relative to average drawdown | 0.81 | 5.60 | -4.78 |
Loading charts...
Drawdowns
AQST vs. DDS - Drawdown Comparison
The maximum AQST drawdown since its inception was -96.68%, roughly equal to the maximum DDS drawdown of -93.62%. Use the drawdown chart below to compare losses from any high point for AQST and DDS.
Loading charts...
Drawdown Indicators
| AQST | DDS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.68% | -93.62% | -3.06% |
Max Drawdown (1Y)Largest decline over 1 year | -60.61% | -24.27% | -36.34% |
Max Drawdown (3Y)Largest decline over 3 years | -63.55% | -42.02% | -21.53% |
Max Drawdown (5Y)Largest decline over 5 years | -90.11% | -49.71% | -40.40% |
Max Drawdown (10Y)Largest decline over 10 years | — | -76.57% | — |
Current DrawdownCurrent decline from peak | -78.01% | -12.84% | -65.17% |
Average DrawdownAverage peak-to-trough decline | -76.92% | -35.61% | -41.31% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 32.01% | 10.47% | +21.54% |
Volatility
AQST vs. DDS - Volatility Comparison
Aquestive Therapeutics, Inc. (AQST) has a higher volatility of 21.51% compared to Dillard's, Inc. (DDS) at 10.15%. This indicates that AQST's price experiences larger fluctuations and is considered to be riskier than DDS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| AQST | DDS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 21.51% | 10.15% | +11.36% |
Volatility (6M)Calculated over the trailing 6-month period | 68.41% | 27.84% | +40.57% |
Volatility (1Y)Calculated over the trailing 1-year period | 85.07% | 39.57% | +45.50% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 82.62% | 50.28% | +32.34% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 87.69% | 59.53% | +28.16% |
Dividends
AQST vs. DDS - Dividend Comparison
AQST has not paid dividends to shareholders, while DDS's dividend yield for the trailing twelve months is around 5.11%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
AQST Aquestive Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
DDS Dillard's, Inc. | 5.11% | 5.13% | 6.02% | 5.18% | 4.89% | 6.41% | 0.95% | 0.68% | 0.66% | 0.57% | 0.45% | 0.40% |
Financials
AQST vs. DDS - Financials Comparison
This section allows you to compare key financial metrics between Aquestive Therapeutics, Inc. and Dillard's, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
AQST vs. DDS - Profitability Comparison
AQST - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Aquestive Therapeutics, Inc. reported a gross profit of 0.00 and revenue of 14.45M. Therefore, the gross margin over that period was 0.0%.
DDS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Dillard's, Inc. reported a gross profit of 0.00 and revenue of 1.57B. Therefore, the gross margin over that period was 0.0%.
AQST - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Aquestive Therapeutics, Inc. reported an operating income of -4.20M and revenue of 14.45M, resulting in an operating margin of -29.1%.
DDS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Dillard's, Inc. reported an operating income of 0.00 and revenue of 1.57B, resulting in an operating margin of 0.0%.
AQST - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Aquestive Therapeutics, Inc. reported a net income of -8.06M and revenue of 14.45M, resulting in a net margin of -55.8%.
DDS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Dillard's, Inc. reported a net income of 250.60M and revenue of 1.57B, resulting in a net margin of 16.0%.
Frequently Asked Questions
AQST and DDS have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
AQST has higher volatility (21.51%) compared to DDS (10.15%). In terms of maximum drawdown, AQST dropped -96.68% vs DDS's -93.62%.
DDS currently has the higher Sharpe Ratio (1.48 vs 0.31), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for AQST and DDS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer